

## References

### R-5060

1. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. *Cancer*. Jul 01 2008; 113(1): 5-21. PMID 18473355
2. Bohnenberger H, Dinter H, Konig A, et al. Neuroendocrine tumors of the thymus and mediastinum. *J Thorac Dis*. Nov 2017; 9(Suppl 15): S1448-S1457. PMID 29201448
3. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol*. Oct 01 2017; 3(10): 1335-1342. PMID 28448665
4. Frilling A, Akerstrom G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. *Endocr Relat Cancer*. Oct 2012; 19(5): R163-85. PMID 22645227
5. Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. *Cancer*. Sep 15 2014; 120(18): 2814-23. PMID 24771552
6. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. *Pancreas*. Apr 2009; 38(3): 255-8. PMID 19066493
7. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. *Endocr Relat Cancer*. Apr 2013; 20(2): 187-96. PMID 23319495
8. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*. Oct 01 2009; 27(28): 4656-63. PMID 19704057
9. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol*. Aug 2015; 26(8): 1604-20. PMID 25646366
10. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). *Gut*. Jan 2012; 61(1): 6-32. PMID 22052063
11. Berg K, Leyden J, Goldstein G, et al. Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis [abstract]. *Endocrine Abstracts*. 2015;37:EP1139.

12. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. *Cancer*. Feb 15 2000; 88(4): 770-6. PMID 10679645
13. Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). *Gastrointest Cancer Res*. Jul 2013; 6(4 Suppl 1): S10-2. PMID 24312683
14. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med*. Feb 10 2011; 364(6): 514-23. PMID 21306238
15. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet*. Mar 05 2016; 387(10022): 968-977. PMID 26703889
16. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet*. Dec 10 2011; 378(9808): 2005-2012. PMID 22119496
17. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med*. Feb 10 2011; 364(6): 501-13. PMID 21306237
18. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. *Neuroendocrinology*. 2016; 103(2): 186-94. PMID 26731334
19. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. Jun 2014; 99(6): 1915-42. PMID 24893135
20. Adjalle R, Plouin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. *Horm Metab Res*. Sep 2009; 41(9): 687-96. PMID 19672813
21. Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics and management update. *Curr Oncol*. Feb 2014; 21(1): e8-e17. PMID 24523625
22. Hamidi O, Young WF, Gruber L, et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. Nov 2017; 87(5): 440-450. PMID 28746746
23. Hamidi O, Young WF, Iniguez-Ariza NM, et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. *J Clin Endocrinol Metab*. Sep 01 2017; 102(9): 3296-3305. PMID 28605453

24. Pheochromocytoma and Paraganglioma Treatment. National Cancer Institute. <https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq>. Accessed June 10, 2022.
25. Gunawardane PTK, Grossman A. Pheochromocytoma and Paraganglioma. *Adv Exp Med Biol*. 2017; 956: 239-259. PMID 27888488
26. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. *J Endocrinol Invest*. Dec 1997; 20(11): 648-58. PMID 9492103
27. Bleeker G, Schoot RA, Caron HN, et al. Toxicity of upfront I-metaiodobenzylguanidine (I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis. *Eur J Nucl Med Mol Imaging*. Oct 2013; 40(11): 1711-7. PMID 23921531
28. Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. *Cancer*. Jun 01 2012; 118(11): 2804-12. PMID 22006217
29. Fliedner SM, Lehnert H, Pacak K. Metastatic paraganglioma. *Semin Oncol*. Dec 2010; 37(6): 627-37. PMID 21167381
30. Ayala-Ramirez M, Chougnat CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. *J Clin Endocrinol Metab*. Nov 2012; 97(11): 4040-50. PMID 22965939
31. Novartis. Novartis provides update on production of radioligand therapy medicines. May 5, 2022; <https://www.novartis.com/news/media-releases/novartis-provides-update-production-radioligand-therapy-medicines>. Accessed on June 10, 2022.
32. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med*. Jan 12 2017; 376(2): 125-135. PMID 28076709
33. Food and Drug Administration, Center for Drug Evaluation and Research. Application Number: 208700Orig1s000 Multi-Disciplinary Review. Addendum to Review, NDA 208700. 2018; [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2018/208700Orig1s000MultidisciplineR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000MultidisciplineR.pdf). Accessed June 10, 2022.
34. Novartis Inc. Lutathera (lutetium Lu 177 dotatate) injection, for intravenous use administration of Lutathera (Prescribing Label). 2018; [https://hcp.lutathera.com/wp-content/uploads/2019/09/LUTATHERA\\_lutetium\\_Lu\\_177\\_dotatate\\_FDA\\_Prescribing\\_Information.pdf](https://hcp.lutathera.com/wp-content/uploads/2019/09/LUTATHERA_lutetium_Lu_177_dotatate_FDA_Prescribing_Information.pdf). Accessed June 10, 2022.

35. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol*. May 01 2008; 26(13): 2124-30. PMID 18445841
36. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. *Clin Cancer Res*. Aug 15 2017; 23(16): 4617-4624. PMID 28428192
37. Zidan L, Iravani A, Oleinikov K, et al. Efficacy and Safety of 177 Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. *J Nucl Med*. Feb 2022; 63(2): 218-225. PMID 34049983
38. FDA- Multi-Discipline Review for NDA/BLA- AZEDRA, 131I-MIBG. Access on May 19, 2020. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2018/209607Orig1s000MultidisciplineR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209607Orig1s000MultidisciplineR.pdf)
39. Prescribing Label AZEDRA (iobenguane I 131) injection, for intravenous use. Access on May 11, 2020 <https://azedra.com/full-prescribing-information.pdf>
40. Satapathy S, Mittal BR, Bhansali A. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. *Clin Endocrinol (Oxf)*. Dec 2019; 91(6): 718-727. PMID 31569282
41. Severi S, Bongiovanni A, Ferrara M, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. *ESMO Open*. Aug 2021; 6(4): 100171. PMID 34139487
42. Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. *J Clin Endocrinol Metab*. Sep 01 2017; 102(9): 3278-3287. PMID 28605448
43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/neuroendocrine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf). Accessed June 10, 2022.